ResearcherUniversity of BergenNo recent work listed
Ragnhild Haugse
Matched on ORCID iD 0000-0001-8793-3097; OpenAlex author ID A5083565975. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2020: 1 paper · 2021: none · 2022: 1 paper
Papers 2
- SonoVue® vs. Sonazoid™ vs. Optison™: Which Bubble Is Best for Low-Intensity Sonoporation of Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.3390/pharmaceutics14010098↗
- Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Cells. Co-author DOI 10.3390/pharmaceutics12111058↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Odd Helge Gilja · 2 shared papers, 2020–2022 · strength 0.26
- Paper SonoVue® vs. Sonazoid™ vs. Optison™: Which Bubble Is Best for Low-Intensity Sonoporation of Pancreatic Ductal Adenocarc… DOI 10.3390/pharmaceutics14010098↗
- Paper Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Cel… DOI 10.3390/pharmaceutics12111058↗
- Spiros Kotopoulis · 2 shared papers, 2020–2022 · strength 0.26
- Paper SonoVue® vs. Sonazoid™ vs. Optison™: Which Bubble Is Best for Low-Intensity Sonoporation of Pancreatic Ductal Adenocarc… DOI 10.3390/pharmaceutics14010098↗
- Paper Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Cel… DOI 10.3390/pharmaceutics12111058↗
- Emmet McCormack · 2 shared papers, 2020–2022 · strength 0.26
- Paper SonoVue® vs. Sonazoid™ vs. Optison™: Which Bubble Is Best for Low-Intensity Sonoporation of Pancreatic Ductal Adenocarc… DOI 10.3390/pharmaceutics14010098↗
- Paper Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Cel… DOI 10.3390/pharmaceutics12111058↗
- Tormod Karlsen Bjånes · 1 shared paper, 2022 · strength 0.15
- Georg Gjorgji Dimcevski · 1 shared paper, 2022 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.